AEON vs. ATAI, ENTA, XBIT, IMMP, ME, DSGN, ACRV, FHTX, ALDX, and TSVT
Should you be buying AEON Biopharma stock or one of its competitors? The main competitors of AEON Biopharma include Atai Life Sciences (ATAI), Enanta Pharmaceuticals (ENTA), XBiotech (XBIT), Immutep (IMMP), 23andMe (ME), Design Therapeutics (DSGN), Acrivon Therapeutics (ACRV), Foghorn Therapeutics (FHTX), Aldeyra Therapeutics (ALDX), and 2seventy bio (TSVT). These companies are all part of the "pharmaceutical preparations" industry.
Atai Life Sciences (NASDAQ:ATAI) and AEON Biopharma (NASDAQ:AEON) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.
AEON Biopharma has lower revenue, but higher earnings than Atai Life Sciences.
In the previous week, Atai Life Sciences had 4 more articles in the media than AEON Biopharma. MarketBeat recorded 5 mentions for Atai Life Sciences and 1 mentions for AEON Biopharma. AEON Biopharma's average media sentiment score of 1.03 beat Atai Life Sciences' score of 1.00 indicating that Atai Life Sciences is being referred to more favorably in the media.
AEON Biopharma has a net margin of 0.00% compared to AEON Biopharma's net margin of -12,810.51%. Atai Life Sciences' return on equity of 0.00% beat AEON Biopharma's return on equity.
Atai Life Sciences received 322 more outperform votes than AEON Biopharma when rated by MarketBeat users. However, 100.00% of users gave AEON Biopharma an outperform vote while only 65.99% of users gave Atai Life Sciences an outperform vote.
Atai Life Sciences has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, AEON Biopharma has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500.
Atai Life Sciences presently has a consensus target price of $10.50, suggesting a potential upside of 532.53%. AEON Biopharma has a consensus target price of $6.00, suggesting a potential upside of 334.78%. Given AEON Biopharma's higher possible upside, equities research analysts clearly believe Atai Life Sciences is more favorable than AEON Biopharma.
28.4% of Atai Life Sciences shares are held by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are held by institutional investors. 31.2% of Atai Life Sciences shares are held by insiders. Comparatively, 20.0% of AEON Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Atai Life Sciences beats AEON Biopharma on 10 of the 14 factors compared between the two stocks.
Get AEON Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for AEON and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AEON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AEON Biopharma Competitors List
Related Companies and Tools
